| Autor: |
Asif, Samia, Fatima, Rawish, Krc, Rebecca, Bennett, Joseph, Raza, Shahzad |
| Zdroj: |
CNS Oncology; June 2020, Vol. 0 Issue: 0 |
| Abstrakt: |
Aim:Glioblastoma multiforme (GBM) carries a dismal prognosis. Integrated proteogenomic analysis was performed to understand GBM pathophysiology. Patients & methods:17 patient samples were analyzed for driver mutations, oncogenes, major pathway alterations and molecular changes at gene and protein level. Clinical, treatment and survival data were collected. Results:Significantly mutated genes included TP53, EGFR, PIK3R1, PTEN, NF1, RETand STAG2. EGFR mutations noted included EGFRvIII-expression, EGFR-L816Qmissense mutation-exon 21 and EGFR fusion (FGFR3-TACC3). TP53mutations were noticed in COSMIC hot-spot driver gene and accompany IDH1and ATRXmutations suggesting low- to high-grade glioma transformation. Proteomics showed higher (53%) EGFR expression than genomic expression (23%). MGMT methylation was present in two-thirds of cases. Conclusion:This study identifies a distinct biological process that may characterize each GBM differently. Proteogenomic data identify potential therapeutic targets of GBM. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
